BSEAGM/EGM1d ago · 4 Sept 2026, 12:37 pm

The 13th Annual General Meeting ("AGM") of the Company will be held on Saturday, September 26, 2026 at 04:00 p.m. IST through Video Conferencing / Other Audio-Visual Means

Trident Lifeline Ltd · 543616

✦ AI SummaryResults

Trident Lifeline Ltd has announced the 13th Annual General Meeting (AGM) to be held on September 26, 2026, through video conferencing. The company has also submitted its Annual Report for the financial year 2025-26, which includes the Notice of AGM, and has fixed September 19, 2026, as the cut-off date for ascertaining the names of members entitled to cast their votes electronically.

Analysis Scores

Earnings Impact5/10
Growth Catalyst3/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Trident Lifeline Ltd - 543616 - Notice Of 13Th Annual General Meeting Of The Company

Attachments (1)

📄

72bebaba-a543-437e-b51b-702bcd9a5eb4.pdf

pdf

Download →
View document text
Date: 04.09.2026 BSE Limited Stock ID: TLL 14th Floor, P. J. Towers, Scrip Code: 543616 Dalal Street, Fort, Mumbai – 400001. Sub: Notice of the 13th Annual General Meeting along with the Annual Report of the Company for the Financial Year 2025‐26 In continuous with our letter dated August 26, 2026 and September 04, 2026, this is to inform that the 13th Annual General Meeting ("AGM") of the Company will be held on Saturday, September 26, 2026 at 04:00 p.m. IST through Video Conferencing / Other Audio-Visual Means in accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. Pursuant to Regulation 34(1) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we are submitting herewith the Annual Report of the Company along with the Notice of AGM for the financial year 2025-26 which is being sent through electronic mode to the Members. The Annual Report containing the Notice is also uploaded on the Company's website and can be accessed at www.tridentlifeline.com. We would further like to inform that the Company has fixed Saturday, September 19, 2026, as the cut‐off date for ascertaining the names of the members of the Company, who will be entitled to cast their votes electronically in respect of the businesses to be transacted as per the Notice of the AGM and to attend the AGM. The remote e-voting period begins on Wednesday, September 23, 2026 at 09:00 a.m. and ends on Friday, September 25, 2026 at 05:00 p.m. Kindly take the above information on record. Thanking you, Yours faithfully FOR TRIDENT LIFELINE LIMITED NIKITA SHARMA COMPANY SECRETARY AND COMPLIANCE OFFICER MEM. NO.: A60595 Encl: As Above Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA. Tel : +91 261 2451274, 2451284 Email : info@tridentlifeline.com Web : www.tridentlifeline.com Factory Address: Plot No. 4240, Road No. 42, Sachin GIDC, Surat, Gujarat - 394230, India. TRIDENT LIFELINE LIMITED Connecting Possibilities. Creating Access. Annual Report 2025-26 Connecting Healthcare reaches people FY26 marked a meaningful step in bringing these capabilities together. Our registration base through a series of connections: continues to open pathways into new markets, between a product and the while our manufacturing infrastructure, product Possibilities. portfolio, in-house R&D and expanding healthcare market it serves, an approval ecosystem strengthen our ability to respond to and the opportunity it unlocks, market opportunities. Across pharmaceuticals, injectables, medical devices, wellness and a manufacturing capability Creating personal care, the focus is moving towards and the demand it can fulfil. creating greater depth in what we offer and greater reach for where we can serve. At Trident Lifeline, these connections have increasingly Connecting Possibilities. Access. shaped the way we think Creating Access. about growth. Over the reflects this direction. We see possibilities in years, investments in product the products we develop, the markets we enter, the capabilities we bring together and the registrations, manufacturing, partnerships we build. Our task is to connect R&D, partnerships and market these possibilities with the people and markets that need them. As Trident Lifeline enters its capabilities have created the next phase, these connections will shape how building blocks for a business we pursue growth, deepen market access and create enduring value for customers, partners, with a wider role across the shareholders and the communities we serve. pharmaceutical value chain. Inside this report Strategic Review Statutory Reports 02 About the Company 30 C orporate Information 06 Capabilities & 31 Board's Report Global Reach 10 Growth Strategy Financial Statements 12 Value Chain 14 Healthcare Offerings 54 S tandalone Financial Statements 16 Chairman's Message 97 Consolidated 18 Key Performance Financial Statements Indicators 20 Board of Directors 22 Management Notice For more info contact us, or visit Discussion and Analysis the website 140 Notice www.tridentlifeline.com Forward Looking Statement This Annual Report contains forward-looking statements intended to provide investors with insights into our future outlook and assist in informed decision-making. These statements, along with other periodic written and verbal communications, reflect our current plans, expectations, and assumptions made by management. Words such as ‘anticipate’, ‘believe’, ‘estimate’, ‘expect’, ‘intend’, ‘plan’, ‘project’, and other similar expressions typically indicate such forward-looking statements. While these statements are based on assumptions we believe to be reasonable at the time, they are inherently subject to known and unknown risks, uncertainties, and other factors that could cause actual outcomes to differ materially from those expressed or implied. Any such divergence may result from changes in the business environment, market dynamics, regulatory shifts, or inaccuracies in assumptions. Given these inherent uncertainties, readers are advised to exercise caution in relying on forward-looking information. We undertake no obligation to update any forward-looking statements publicly, whether as a result of new information, future developments, or otherwise. STRATEGIC REVIEW STATUTORY REPORTS FINANCIAL STATEMENTS Trident Lifeline Limited | Annual Report 2025-26 TRIDENT LIFELINE LIMITED About The Company A Hybrid Manufacturing Model Positioned for the Next Integrated Platform. Built for Scale Phase of Growth The Company's operations are anchored in a Trident Lifeline's growth strategy is hybrid manufacturing model that combines centred on innovation, operational Global Reach. owned facilities with contract manufacturing scale, and the sustained expansion of its partnerships, allowing production to be customer base and product registrations. scaled efficiently while capital discipline is Some of its newer ventures, notably the maintained. In preference to establishing injectables and nutraceutical businesses, Trident Lifeline Limited is an export-focused pharmaceutical Company that new facilities alone, Trident Lifeline has remain at an early stage, with revenue has grown into a diversified, multi-vertical healthcare enterprise. The Company consistently pursued strategic investments and contribution expected from FY27 as competes on the quality, reliability, and breadth of its offering, underpinned acquisitions in valuable manufacturing assets, facilities are commissioned and capacity thereby deepening its participation across the utilisation is progressively built up. by a differentiated hybrid manufacturing approach and disciplined capital pharmaceutical value chain while preserving Supported by a growing manufacturing allocation that together strengthen its competitive position and extend its competitive pricing. Across its export markets, base and a skilled workforce, the reach to a widening global clientele. the Company partners with distributors for Company is positioned to translate these market access and, in turn, serves as their investments into long-term value for dedicated manufacturing and supply partner. all stakeholders. F The Integrated Trident Ecosystem 5 10+ 80 Crore Building a diversified manufacturing platform across formulations and medical devices Business Years of Intrinsic Value Verticals Experience of Registrations aD nr dy SP ao cw hd ee tsr D ar ny dP So aw chd ee tr s (TableO tr sa O (Tara bl l eS to s,l i Cd as psules) 40% 4 a p sd s ules) e Capacity Manufacturing bl po (S Utilisation Facilities tam r u cA p (VialsIn Aje mc pta oub ll ee ss uloS ,s diuqiL (L Si yq ru ui pd ss , Solutions) ( t s F oi 129.0 21.8% n Crore ) F (CY o2 n6 s R oe liv de an teu de ) F M (CY a o2 r n6 g iE onB idIT aD teA d ) Medical Devices dd Sic ua rl gD ie cv aic les aO ni dnt Tm oe pn it [Showing first 8,000 characters — download PDF for full document]